Mdxhealth S.A. ( (MDXH) ) has released its Q1 earnings. Here is a breakdown of the information Mdxhealth S.A. presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
MDxHealth SA is a precision diagnostics company specializing in molecular information to aid in the diagnosis and treatment of urologic cancers and diseases, operating primarily in the healthcare sector with a focus on genomic and epigenetic technologies.
In its latest earnings report for the first quarter of 2025, MDxHealth announced a significant 22% increase in year-over-year revenue, reaching $24.3 million. The company also reported a notable 71% improvement in adjusted EBITDA, reflecting strong operational execution and growing demand for its diagnostic tests.
Key financial highlights include a gross profit increase of 29% to $15.5 million, driven by a favorable test mix that improved gross margins to 63.8%. The company’s tissue-based test volumes rose by 41%, while liquid-based test volumes saw a 9% increase. Despite a net loss of $9.2 million, the adjusted EBITDA showed a marked improvement, indicating progress towards profitability.
Operating expenses rose by 8% due to higher clinical trial costs and stock-based compensation, while the company’s cash and cash equivalents stood at $65.7 million at the end of the quarter. The company reiterated its revenue guidance for 2025, projecting $108-110 million and expects to achieve adjusted EBITDA profitability in the second quarter.
Looking ahead, MDxHealth remains focused on expanding its market presence and achieving profitability, supported by its strategic initiatives and continued demand for its precision diagnostics solutions.